Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature Research
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.22/16649 |
Resumo: | In 2019, an outbreak of an unknown coronavirus – SARS-CoV-2 – responsible for COVID-19 disease, was first reported in China, and evolved into a pandemic of huge dimensions and raised serious concerns for global health. The number of critical cases continues to increase dramatically, while vaccines and specific treatments are not yet available. There are several strategies currently being studied for the treatment of adverse symptoms of COVID-19, that encompass Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS), extensive pulmonary inflammation, cytokine storm, and pulmonary edema, due to virus-induced pneumonia. |
id |
RCAP_f2c5fcb94ce0ebcea5ee194f108a0f1e |
---|---|
oai_identifier_str |
oai:recipp.ipp.pt:10400.22/16649 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature ResearchCell-based therapiesSecretomeMesenchymal stem cellsCoronavirusSARS-CoV-2In 2019, an outbreak of an unknown coronavirus – SARS-CoV-2 – responsible for COVID-19 disease, was first reported in China, and evolved into a pandemic of huge dimensions and raised serious concerns for global health. The number of critical cases continues to increase dramatically, while vaccines and specific treatments are not yet available. There are several strategies currently being studied for the treatment of adverse symptoms of COVID-19, that encompass Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS), extensive pulmonary inflammation, cytokine storm, and pulmonary edema, due to virus-induced pneumonia.Frontiers in Cell and Developmental BiologyRepositório Científico do Instituto Politécnico do PortoCoelho, AndréAlvites, Rui DamásioBranquinho, Mariana VieiraGuerreiro, Susana G.Maurício, Ana Colette2021-01-05T11:37:07Z2020-11-192020-11-19T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/16649engCoelho, A., Alvites, R. D., Branquinho, M. V., Guerreiro, S. G., & Maurício, A. C. (2020). Mesenchymal Stem Cells (MSCs) as a Potential Therapeutic Strategy in COVID-19 Patients: Literature Research. Frontiers in Cell and Developmental Biology, 8, 602647. https://doi.org/10.3389/fcell.2020.60264710.3389/fcell.2020.602647info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-13T01:49:53Zoai:recipp.ipp.pt:10400.22/16649Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:36:17.450646Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature Research |
title |
Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature Research |
spellingShingle |
Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature Research Coelho, André Cell-based therapies Secretome Mesenchymal stem cells Coronavirus SARS-CoV-2 |
title_short |
Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature Research |
title_full |
Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature Research |
title_fullStr |
Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature Research |
title_full_unstemmed |
Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature Research |
title_sort |
Mesenchymal Stem Cells (MSCs) as a potential therapeutic Strategy in COVID-19 Patients: Literature Research |
author |
Coelho, André |
author_facet |
Coelho, André Alvites, Rui Damásio Branquinho, Mariana Vieira Guerreiro, Susana G. Maurício, Ana Colette |
author_role |
author |
author2 |
Alvites, Rui Damásio Branquinho, Mariana Vieira Guerreiro, Susana G. Maurício, Ana Colette |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Politécnico do Porto |
dc.contributor.author.fl_str_mv |
Coelho, André Alvites, Rui Damásio Branquinho, Mariana Vieira Guerreiro, Susana G. Maurício, Ana Colette |
dc.subject.por.fl_str_mv |
Cell-based therapies Secretome Mesenchymal stem cells Coronavirus SARS-CoV-2 |
topic |
Cell-based therapies Secretome Mesenchymal stem cells Coronavirus SARS-CoV-2 |
description |
In 2019, an outbreak of an unknown coronavirus – SARS-CoV-2 – responsible for COVID-19 disease, was first reported in China, and evolved into a pandemic of huge dimensions and raised serious concerns for global health. The number of critical cases continues to increase dramatically, while vaccines and specific treatments are not yet available. There are several strategies currently being studied for the treatment of adverse symptoms of COVID-19, that encompass Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS), extensive pulmonary inflammation, cytokine storm, and pulmonary edema, due to virus-induced pneumonia. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-11-19 2020-11-19T00:00:00Z 2021-01-05T11:37:07Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.22/16649 |
url |
http://hdl.handle.net/10400.22/16649 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Coelho, A., Alvites, R. D., Branquinho, M. V., Guerreiro, S. G., & Maurício, A. C. (2020). Mesenchymal Stem Cells (MSCs) as a Potential Therapeutic Strategy in COVID-19 Patients: Literature Research. Frontiers in Cell and Developmental Biology, 8, 602647. https://doi.org/10.3389/fcell.2020.602647 10.3389/fcell.2020.602647 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers in Cell and Developmental Biology |
publisher.none.fl_str_mv |
Frontiers in Cell and Developmental Biology |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131453828628480 |